PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India; Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 5thAugust, 2019

To National Stock Exchange of India Limited Exchange Plaza Plot No. C/1, G Block Bandra Kurla Complex Bandra (E), Mumbai- 400051

To Bombay Stock Exchange Limited Phiroze Jejeebhoy Towers Rotund Bldg., Dalal Street Mumbai- 400051

SYMBOL: PDPL

Scrip Code: 524689

Sub:- Submission of Unaudited Financial Results for the Quarter ended on 30th June, 2019

Dear Sir/Ma'am

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Unaudited Financial Results of the Company (Standalone and Consolidated basis) for the quarter ended 30th June, 2019.

This is for the information of the Exchange and Members thereof.

Kindly take the same on record.

Thanking You For Parenteral Drugs (India) Limited

Surachi Maheshwari Company Secretary

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com; CIN: L24100MH1983PLC126481





www.jas-anz.org/register

PDPL.

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India; Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE I QUARTER ENDED ON 30TH JUNE , 2019

Sr. No.	. Particulars	(Rs in Lakh, unless otherwise stated)				
		Quarter Ended 30-06-2019 (Un-Audited)	Quarter Ended 31-03-2019 (Audited)	Quarter Ended 30-06-2018 (Un-Audited)	Year Ended 31-03-2019 (Audited)	
	Income					
I	(a) Revenue From Operation (Net of excise duty)	871.60	239.07	1,056.32	3,202.78	
ñ	(b) Other Operating Income	1.30	139.91	2.41	143.52	
	Total Income (I+II)	872.90	378.98	1,058.73	3,346.30	
IV	Expenditure					
	Cost of Material Consumed	151.76	6.33	196.18	757.17	
	Purchase of Stock In Trade		-	-	-	
	Change in Inventories of Finished Goods, Stock In trade and Work in					
	Progress	109.54	60.10	(46.79)	(111.15	
	Employee Benefit Expenses	455.62	536.13	497.83	1,994.02	
	Finance costs	2,599.19	2,490.61	2,285.46	9,605.44	
	Depreciation, Amortisation and Impairment Expenses	434.30	5,520.18	464.89	6,911.93	
	Other Expenditure	552.03	563.09	637.44	2,328.39	
	Total Expenses (IV)	4,302.44	9,176.44	4,035.01	21,485.80	
V	Profit / (Loss) before exceptional	4,302.44	9,170.44	4,035.01	21,485.80	
	items and Tax (I-IV)	(3,429.54)	(8,797.46)	(2,976.28)	(18,139.50	
VI	Exceptional items		-	-	-	
VII	Profit / (Loss) before Tax (V-VI)	(3,429.54)	(8,797.46)	(2,976.28)	(18,139.50	
VIII	Tax Expenses					
	(1) Current Tax			2000 0 10 000		
	(2) Deferred Tax	(660.93)	(1,601.65)	(592.25)	(3,349.06	
IX	Net Profit / (Loss) for the period from continuing operations					
17	(VII-VIII)	(2,768.61)	(7,195.81)	(2,384.03)	(14,790.44	
х	Net Profit / (Loss) for the period from discontinuing operations					
XI	Tax expense of discontinuing operations			-		
	Net Profit / (Loss) from discontinued operations (after Tax)					
XII	(X-XI)					
XIII	Profit/(loss) for the period (IX+XII)	(2,768.61)	(7,195.81)	(2,384.03)	(14,790.44	
XIV	Other Comprehensive Income					
	A (i) Item that will not be reclassified to Profit or loss	(1.48)	(21.80)	(1.09)	(25.07	
	(ii) Income tax relation to Item that will not be reclassified to					
	Profit or loss	-		-		
	B (i) Item that will be reclassified to Profit or loss	-		÷		
	(ii) Income tax relation to Item that will be reclassified to Profit					
	or loss	-		-		
	Total comprehensive Income for the period					
XV	(XIII+XIV)(comprising profit (loss) and other comprehensive					
	income for the period)	(2,770.09)	(7,217.61)	(2,385.12)	(14,815.51	
XVI	Paid Up Equity share capital(Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	
XVII	Earnings per share (for continuing operation):					
	(a) Basic (In Rs.)	(9.29)	(24.13)	(8.00)	(49.61	
	(b) Diluted (In Rs.)	(9.29)	(24.13)	(8.00)	(49.61	
XVIII	Earnings per share (for discontinued operation):					
	(a) Basic (In Rs.)	-	-	-	-	
	(b) Diluted (In Rs.)	-	-	-	-	
XIX	Earnings per share (for discontinued & continuing operation) :					
		(9.29)	(24.13)	(8.00)	(49.61	
	(a) Basic (In Rs.)	(9.29)	(24.13)	(8.00)	(49.01	
3	(b) Diluted (In Rs.)	(9.29)	(24.13)	(8.00)	(49.61	

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com; CIN: L24100MH1983PLC126481



UGS



0

PARENTERAL DRUGS (INDIA) LIN

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India; Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com


Notes to the financial results:

PDPL.

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in 1 their meeting held on 05-08- 2019.
- The above standalone financial results for the quarter ended 30 th June 2019 have been prepared in accordance with the 2 Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017.
- At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) 3 as the business under proposed real estate segment is yet to commence.
- The figures for the quarter ended March 31, 2019 are the balancing figures between audited figures in respect of the full 4 financial year and the unaudited published figures upto nine months of the financial year.
- The previous period figures have been regrouped/rearranged wherever found necessary. 5
- The Standalone financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on 6 website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

Place: Indore Date: 05-08-2019

Vinod Kumar Gupta Managing Director DIN 00039145



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com; CIN: L24100MH1983PLC126481





PDPL

PARENTERAL DRUGS (INDIA) LIMITED Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;


Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE I QUARTER ENDED ON 30 TH JUNE, 2019

30-06-2019 31-03-2019 (Audited) (Audited) 1 (b) Other Income (1-3) 133.91 16.74 143. 111 Total Income (1+11) 872.90 378.98 4.924.80 3346. Charder Intreenders of Finished Goods, Stock In trade and Work in 0.00 102.66 0.00 126.65 0.00 Progress 613.00 (764.25) 111 0.00 126.64 0.00 126.65 0.00 Other Expenditure 550.03 550.03 605.84 601.01 (764.25) 111 Other Expenses (1V) 3302.44 9176.44 7956.84 21485.01 VI Profit / Loss) before exceptional (a.932.041 <th></th> <th></th> <th>(Rs</th> <th>s in Lakh,unless o</th> <th>otherwise stated</th> <th>)</th>			(Rs	s in Lakh,unless o	otherwise stated)
III (b) Other Income 1.30 139.91 16.74 143. IIII Total Income (I+II) 872.90 378.98 4.924.80 3346. IV Expenditure 0.00 0.00 192.62 0. Charge in Inventores of Finished Goods, Stock In trade and Work in 0.00 0.00 192.62 0. Progress 495.62 536.13 678.55 1994 4 111. Charge In Inventories of Finished Goods, Stock In trade and Work in 109.54 60.10 (764.25) 111. Employee Benefit Expenses 435.02 366.09 1.51.72 2.355.07 9605. Depreciation and Amortisation Expenses 434.30 5520.18 0.668.46 631.1 Other Expenditure 532.03 66.09 1.6.74 2328. V Profit / (Loss) before excuptonal tems 13.422.54) (8.797.46) (3.032.04) 118.139.5 VII Profit / (Loss) for the period from continuing operations (VII- (2.768.61) (7.195.81) (2.457.85) (14.790.4 X	Sr. No.		30-06-2019	31-03-2019	30-06-2018	Year Ended 31-03-2019 (Audited)
III (b) Other Income 1.30 139.91 16.74 143. IIII Total Income (I+II) 872.90 378.98 4.924.80 3346. IV Expenditure 0.00 0.00 192.62 0. Charge in Inventores of Finished Goods, Stock In trade and Work in 0.00 0.00 192.62 0. Progress 495.62 536.13 678.55 1994 4 111. Charge In Inventories of Finished Goods, Stock In trade and Work in 109.54 60.10 (764.25) 111. Employee Benefit Expenses 435.02 366.09 1.51.72 2.355.07 9605. Depreciation and Amortisation Expenses 434.30 5520.18 0.668.46 631.1 Other Expenditure 532.03 66.09 1.6.74 2328. V Profit / (Loss) before excuptonal tems 13.422.54) (8.797.46) (3.032.04) 118.139.5 VII Profit / (Loss) for the period from continuing operations (VII- (2.768.61) (7.195.81) (2.457.85) (14.790.4 X	I	(a) Revenue From Operation(Net of excise duty)	871.60	239.07	4,908.06	3202.7
III Total Income [1+II) 872.90 378.98 4,924.80 3346. IV Expenditure 151.76 6.33 2,872.79 757. Purchase of Stock In Trade 0.00 0.00 100.262 70.0 Change in Inventories of Finished Goods,Stock In trade and Work in Progress 0.00 0.00 102.62 70.0 Change in Inventories of Finished Goods,Stock In trade and Work in Progress 0.00 0.00 102.62 70.0 Employee Benfit Expenses 455.62 536.13 678.55 1994. Finance costs 2559.19 2490.61 2,552.03 160.54 660.54 661. 152.12 2328. Total Expenses (IV) 4302.44 9176.44 7956.84 21485. 7956.84 21485. 7957.461 (3.032.04) 118.139.5 797.461 (3.032.04) 118.139.5 7957.451 (3.032.04) 118.139.5 VIII Tax Expenses 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1	11		1.30	139.91	16.74	143.5
IV Expenditure	III	Total Income (I+II)	872.90	378.98		3346.3
Purchase of Stock In Trade 0.00 0.00 192.62 0.0 Change in Inventores of Finished Goods, Stock In trade and Work in Progress 100.54 60.10 (764.25) 111 Employee Benefit Expenses 435.62 536.13 678.55 1994. Finance costs 2599.19 2490.61 2,555.07 9605. Depreciation and Amortisation Expenses 433.30 552.03 563.09 1,815.22 2228. V Profit / (Loss) before exceptional items and Tax (1-TV) (3,429.54) (8,797.46) (3,032.04) (18,139.5) VII Profit / (Loss) before Tax (V-VI) (3,429.54) (8,797.46) (3,032.04) (18,139.5) VIII Profit / (Loss) before Tax (V-VI) (3,429.54) (8,797.46) (3,032.04) (18,139.5) VIII Profit / (Loss) for the period from continuing operations (VII- (2) Defred Tax (2,66.03) (1601.65) (574.19) (3,490.04) X Net Profit / (Loss) for the period from discontinuing operations (VII- XIII) (2,168.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit / (Loss) from di	Ĩ٧					
Change in Inventories of Finished Goods, Stock In trade and Work in Progress 109.54 60.10 (764.25) Employee Benefit Expenses 435.62 536.13 678.85 1994 Finance costs 2590.19 2490.61 2.555.07 9605 Depreciation and Amortisation Expenses 434.30 5520.18 606.64 6911 Other Expenditure 552.03 563.09 1.815.22 2328. Total Expenses (IV) 4302.44 9176.44 7956.84 21485.1 V Profit / (Loss) before exceptional items and Tax (I-VV) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Profit / (Loss) before Tax (V-VI) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Profit / (Loss) for the period from continuing operations (VII- (2) Deferred Tax (660.93) (1501.65) (574.19) (3349.0 X Net Profit / (Loss) for the period from discontinuing operations - - - - - - - - - - - - - - - -<		Cost of Material Consumed	151.76	6.33	2,872.79	757.1
Progress 109 54 60.10 (764.25) -111 Empores Benefit Expenses 435.62 556.13 678.85 1994 Finance costs 2399.19 2490.61 2,555.07 9605 Depreciation and Amortisation Expenses 434.30 552.03 563.09 1,815.22 2328. Total Expenses (IV) 4302.44 9176.44 7956.84 21485. VI Exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII Track Expenses (13,0429.54) (8,797.46) (3,032.04) (18,139.5 VIII Track Expenses (14,055) (1601.65) (574.19) (3349.0 VIII Track Expenses (14,055) (14,790.4) (2,0768.61) (7,195.81) (2,457.85) (14,790.4 X Net Profit / (Loss) for the period from discontinuing operations - - - - - - - - - - - - - - - - - -		Purchase of Stock In Trade	0.00	0.00	192.62	0.0
Employee Benefit Expenses 455.62 536.13 678.55 1994. Finance costs 2599.19 2490.61 2.555.07 9605. Depreciation and Amortisation Expenses 434.30 5520.18 606.84 6911. Other Expenditure 552.03 563.09 1.815.22 2328. Total Expenses (IV) 4302.44 9176.44 7956.84 21485. V Profit / (Loss) before exceptional items and Tax (I-IV) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII Exceptional items (3.429.54) (8,797.46) (3,032.04) (18,139.5 VIII Total Expenses (1601.65) (574.19) (3349.0 XIII Profit / (Loss) for the period from continuing operations (VII- (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Net Profit / (Loss) for the period from discontinuing operations (VII- (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Net Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4		Change in Inventories of Finished Goods, Stock In trade and Work in				
Employee Benefit Expenses 455.62 536.13 678.55 1994. Finance costs 2599.19 2490.61 2.555.07 9605. Depreciation and Amortisation Expenses 434.30 5520.18 606.84 6911. Other Expenditure 552.03 563.09 1.815.22 2328. Total Expenses (IV) 4302.44 9176.44 7956.84 21485.7 V Profit / (Loss) before exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII Exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Total Expenses (1601.65) (574.19) (3349.0 XIII Frofit / (Loss) for the period from continuing operations (VII- (2,258.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit / (Loss) for the period from discontinuing operations (VII- (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Net Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII		Progress	109 54	60.10	(764.25)	-111.1
Finance costs 2599.19 2490.61 2.555.07 9605. Depreciation and Amortisation Expenses 434.30 555.03 606.8.4 6911. Other Expenditure 552.03 553.09 1.815.22 2328. Total Expenses (IV) 4302.44 9176.44 7956.84 21485.1 V Profit / (Loss) before exceptional items and Tax (I-IV) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII. Tax Expenses (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII. Tax Expenses (3,032.04) (18,139.5 (10,00000000000000000000000000000000000						
Depreciation and Amortisation Expenses 434 30 5520.18 606.84 6011 Other Expenditure 552.03 563.09 1.815.22 2328. Total Expenses (IV) 4302.44 9176.44 7956.84 21485. V Profit / (Loss) before exceptional items and Tax (I-IV) (3,429.54) (8,797.46) (3032.04) (18,139.5 VII Exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Forfit / (Loss) before Tax (V-VI) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Forfit / (Loss) before Tax (V-VI) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Forfit / (Loss) for the period from continuing operations (VII- (2) Deferred Tax (3,429.54) (8,797.46) (3,032.04) (18,139.5 XIII A versense of discontinued operations (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Revense of discontinued operations (after Tax) (X-XI) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIV Other Comprehensive Income for th						
Other Expenditure 552.03 563.09 1,815.22 2328. Total Expenses (IV) 4302.44 9176.44 7956.84 21485.1 V Profit / (Loss) before exceptional items and Tax (1-TV) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII Exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Tax Expenses (660.93) (1601.65) (574.19) (3349.0 (1) Tax Expenses (660.93) (1601.65) (574.19) (3349.0 (1) Net Profit / (Loss) for the period from discontinuing operations (VII- (12,058.01) (1,2457.85) (14,790.4 XIII Profit / (Loss) from discontinued operations (after Tax) (X-XI) - - - XIII Profit / (Loss) from discontinued operations (after Tax) (X-XI) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit / (Loss) from discontinued operations (after Tax) (X-XI) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit / (Loss) from discontinued operation (ss (1.48) (21.80)						
Total Expenses (IV) 4302.44 9176.44 7956.84 21485.1 V Profit / (Loss) before exceptional items and Tax (I-TV) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII Exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII Exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Total Expenses (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Tax Expenses (660.93) (1601.65) (574.19) (3349.0 IX Net Profit / (Loss) for the period from continuing operations (VII- VIII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 X Net Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Net Profit / (Loss) for the period or period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Net Profit / Ioss) for the period or period (IX+XII) (2,719.58) (2,457.85) (14,790.4 VIII Profit / Ioss) and other						
V Profit / (Loss) before exceptional items and Tax (I-IV) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VI Exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII Tax Expenses (3,249.54) (8,797.46) (3,032.04) (18,139.5 (1) Current Tax (3,029.54) (8,797.46) (3,032.04) (18,139.5 (2) Deferred Tax (660.93) (1601.65) (574.19) (3349.0 (2) Deferred Tax (660.93) (1501.65) (574.19) (3349.0 X Net Profit / (Loss) for the period from continuing operations (VII- VIII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 X Net Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit/(Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit/(Loss) for the period (IX+XII) (2,766.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit/(Loss) for the period (IX+XII) (2,766.61)		Long 1/2 Millionali				
items and Tax (1-IV) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VII Exceptional items (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Tax Expenses (3,429.54) (8,797.46) (3,032.04) (18,139.5 (10) Current Tax (3,029.54) (8,797.46) (3,032.04) (18,139.5 (2) Deferred Tax (660.93) (1601.65) (574.19) (3349.0 X Net Profit / (Loss) for the period from continuing operations - - - - X Net Profit / (Loss) for the period from discontinuing operations -<			4302.44	9176.44	7956.84	21485.8
VI. Exceptional items Construct Construct <thconstruct< th=""> Construct <</thconstruct<>	v		2			
VII Profit / (Loss) before Tax (V-VI) (3,429.54) (8,797.46) (3,032.04) (18,139.5 VIII Tax Expenses (10 Current Tax (20 Deferred Tax (660.93) (1601.65) (574.19) (3349.0 (1) Current Tax (660.93) (1601.65) (574.19) (3349.0 (1x Net Profit / (Loss) for the period from continuing operations (VII- VIII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 X Net Profit / (Loss) for the period from discontinuing operations - <td></td> <td>items and Tax (I-IV)</td> <td>(3,429.54)</td> <td>(8,797.46)</td> <td>(3,032.04)</td> <td>(18,139.50</td>		items and Tax (I-IV)	(3,429.54)	(8,797.46)	(3,032.04)	(18,139.50
VIII Tax Expenses	VI	Exceptional items				
(1) Current Tax - - - (2) Deferred Tax (660.93) (1601.65) (574.19) (3349.0 1x Net Profit / (Loss) for the period from continuing operations (VII- VIII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 X Net Profit / (Loss) for the period from discontinuing operations -	VII	Profit / (Loss) before Tax (V-VI)	(3,429.54)	(8,797.46)	(3,032.04)	(18,139.50
(2) Deferred Tax (660.93) (1601.65) (574.19) (3349.0 IX Net Profit / (Loss) for the period from discontinuing operations (VII- VIII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 X Net Profit / (Loss) for the period from discontinuing operations - - - - XI Tax expense of discontinuing operations (after Tax) (X-XI) - - - - XIII Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 XIII Deter Comprehensive Income (1.48) (21.80) (0.36) (25.0 (ii) Income tax relation to Item that will be reclassified to Profit or loss - - - - XV Proid Up Equity share capital (Face value Rs.10/-each) (2,770.09) (7,217.61) <	VIII	Tax Expenses				
IX Net Profit / (Loss) for the period from continuing operations (VII-VIII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 X Net Profit / (Loss) for the period from discontinuing operations -		(1) Current Tax		-	-	
1X VIII) (2,768.61) (7,195.81) (2,457.85) (14,790.4 X Net Profit / (Loss) for the period from discontinuing operations -		(2) Deferred Tax	(660.93)	(1601.65)	(574.19)	(3349.06
X Net Profit / (Loss) for the period from discontinuing operations (2,78,61) (7,195.81) (2,457.85) (14,790.4) XI Tax expense of discontinuing operations - - - - - XI Tax expense of discontinuing operations - - - - - - - XII Net Profit / (Loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4) XIV Other Comprehensive Income (2,768.61) (7,195.81) (2,457.85) (14,790.4) XIV Other Comprehensive Income (1.48) (21.80) (0.36) (25.0) (ii) Income tax relation to Item that will not be reclassified to Profit or loss - - - - B (1) Item that will be reclassified to Profit or loss -	1.4	Net Profit / (Loss) for the period from continuing operations (VII-				
XI Tax expense of discontinuing operations - - - XII Net Profit / (Loss) from discontinued operations (after Tax) (X-XI) - - - XIII Profit/(loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4) XIV Other Comprehensive Income - <t< td=""><td>17</td><td>VIII)</td><td>(2,768.61)</td><td>(7,195.81)</td><td>(2,457.85)</td><td>(14,790.44</td></t<>	17	VIII)	(2,768.61)	(7,195.81)	(2,457.85)	(14,790.44
XII Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	Х	Net Profit / (Loss) for the period from discontinuing operations		-	· · · · · · · · · · · · · · · · · · ·	-
NIII Profit/(loss) for the period (IX+XII) (2,768.61) (7,195.81) (2,457.85) (14,790.4) XIV Other Comprehensive Income (1.48) (21.80) (0.36) (25.0) (ii) Income tax relation to Item that will not be reclassified to Profit or loss (1.48) (21.80) (0.36) (25.0) 8 (i) Item that will be reclassified to Profit or loss - - - - 8 (i) Item that will be reclassified to Profit or loss - - - - 10 Item that will be reclassified to Profit or loss - <t< td=""><td>XI</td><td>Tax expense of discontinuing operations</td><td>-</td><td></td><td>-</td><td>-</td></t<>	XI	Tax expense of discontinuing operations	-		-	-
XIV Other Comprehensive Income (1.48) (21.80) (0.36) (25.0 A (i) Item that will not be reclassified to Profit or loss (1.48) (21.80) (0.36) (25.0 (ii) Income tax relation to Item that will not be reclassified to Profit or loss - - - - B (i) Item that will be reclassified to Profit or loss - - - - - (ii) Income tax relation to Item that will be reclassified to Profit or loss - - - - - - (ii) Income tax relation to Item that will be reclassified to Profit or loss -	XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-
A (i) Item that will not be reclassified to Profit or loss (1.48) (21.80) (0.36) (25.0 (ii) Income tax relation to Item that will not be reclassified to Profit or loss - <td>XIII</td> <td>Profit/(loss) for the period (IX+XII)</td> <td>(2,768.61)</td> <td>(7,195.81)</td> <td>(2,457.85)</td> <td>(14,790.44</td>	XIII	Profit/(loss) for the period (IX+XII)	(2,768.61)	(7,195.81)	(2,457.85)	(14,790.44
A (i) Item that will not be reclassified to Profit or loss (1.48) (21.80) (0.36) (25.0 (ii) Income tax relation to Item that will not be reclassified to Profit or loss - <td>XIV</td> <td>Other Comprehensive Income</td> <td></td> <td></td> <td></td> <td></td>	XIV	Other Comprehensive Income				
(ii) Income tax relation to Item that will not be reclassified to Profit or loss		A (i) Item that will not be reclassified to Profit or loss	(1.48)	(21.80)	(0.36)	(25.07
B (i) Item that will be reclassified to Profit or loss -		A CONTRACT DE L'ARTE DE				
(ii) Income tax relation to Item that will be reclassified to Profit or loss			-			
XV Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period) (2,770.09) (7,217.61) (2,458.21) (14,815.5 XVI Paid Up Equity share capital(Face value Rs.10/-each) 2,981.63						
XV Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period) (2,770.09) (7,217.61) (2,458.21) (14,815.5 XVI Paid Up Equity share capital(Face value Rs.10/-each) 2,981.63		(ii) Income tax relation to Item that will be reclassified to Profit or loss	_	-	-	-
XV profit (loss) and other comprehensive income for the period) (2,770.09) (7,217.61) (2,458.21) (14,815.5 XVI Paid Up Equity share capital(Face value Rs.10/-each) 2,981.63		Total comprehensive Income for the period (XIII+XIV)/comprising				
profit (loss) and other comprehensive income for the period) (2,770.09) (7,217.61) (2,458.21) (14,815.5 XVI Paid Up Equity share capital (Face value Rs.10/-each) 2,981.63 2,981.6	ΧV	Total comprehensive income for the period (xIII+XIV)(comprising				
XVI Paid Up Equity share capital(Face value Rs.10/-each) 2,981.63	~	profit (loss) and other comprehensive income for the period)	(2,770,09)	(7.217.61)	(2.458.21)	(14.815.51
XVII Earnings per share (for continuing operation): (9.29) (24.13) (8.24) (49.6 (b) Diluted (9.29) (24.13) (8.24) (49.6 (a) Basic (9.29) (24.13) (8.24) (49.6 (a) Basic (9.29) (24.13) (8.24) (49.6 (b) Diluted (9.29) (24.13) (8.24) (49.6 (a) Basic - - - - (b) Diluted - - - - XIX Earnings per share (for discontinued & continuing operation): - - - (a) Basic (9.29) (24.13) (8.24) (49.6) (a) Basic - - - - (a) Basic (9.29) (24.13) (8.24) (49.6)	YVI "					
(a) Basic (9.29) (24.13) (8.24) (49.6 (b) Diluted (9.29) (24.13) (8.24) (49.6 XVIII Earnings per share (for discontinued operation : - - - - (a) Basic - - - - - - - - (b) Diluted -			-1202-000		-(
(b) Diluted (9.29) (24.13) (8.24) (49.6 XVIII Earnings per share (for discontinued operation : - <td></td> <td></td> <td>(9.29)</td> <td>(24.13)</td> <td>(8.24)</td> <td>(49.61</td>			(9.29)	(24.13)	(8.24)	(49.61
XVIII Earnings per share (for discontinued operation :						(49.61
(a) Basic -	XVIII		(5.257	12157		,
(b) Diluted			-	-	-	-
XIX Earnings per share (for discontinued & continuing operation) :						
(a) Basic (9.29) (24.13) (8.24) (49.6			-	-		-
	XIX			10	10 - 1	
(b) Diluted		(a) Basic	(9.29)	(24.13)	(8.24)	(49.61
		(b) Diluted	(9.29)	(24.13)	(8.24)	(49.61



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com; CIN: L24100MH1983PLC126481





www.jas-anz.org/register

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India; Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- 1 The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 05-08- 2019.
- 2 Additional information on standalone financial results are given below:

	Rs. In Lakh			
Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year to
	30-06-2019	31-03-2018	30-06-2018	Ended
	(Un Audited)	(Audited)	(Un Audited)	31-03-2018
				(Audited)
Total Income from operations	872.90	378.98	1,058.73	3,346.30
Profit/Loss before tax	(3,429.54)	(8,797.46)	(2,976.28)	(18,139.50)
Profit/Loss after tax	(2,770.09)	(7,217.61)	(2,385.12)	(14,815.51)

- 3 The above consolidated financial results for the quarter ended 30th June 2019 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017.
- 4 At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting)
- as the business under proposed real estate segment is yet to commence.
- 5 Figures of quarter ended June 2019 do not include the figures of subsidiary company Infutec Healthcare Limited as it has ceased to be a subsidiary w.e.f. 10-07-2018, hence figures are not comparable with preveious corresponding quarter.
- 6 The figures for the quarter ended March 31, 2019 are the balancing figures between audited figures in respect of the full
- financial year and the unaudited published figures upto nine months of the financial year.
- 7 The previous period figures have been regrouped/rearranged wherever found necessary.
- 8 The Consolidated financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Place: Indore Date:05-08-2019 Vinod Kumar Gupta Managing Director DIN 00039145



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com; CIN: L24100MH1983PLC126481





www.jas-anz.org/register



Singhal Jain & Co. CHARTERED ACCOUNTANTS

CA KAMAL JAIN FCA, LL.B., M.COM, PGDTL, FAFP

Limited Review Report of unaudited standalone guarterly and year to date results

Review report to The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of Parenteral Drugs (India) Limited for the period ended 30th June, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is fimited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhal Jain & Co. Chartered Accountants Firm Regn No.013995C

Karnal Jain (Partner) M. No.406604

Place: Indore Date : 05.08.2019 UDIN :- 19406604 AAAAAF3981

A-18, Indrapuri Colony, Lai Kothi, Tonk Road, Jaipur, 302006 (Raj.) +91 8233600787, 0141-4010787 Email :- cajainkamal@gmail.com



Singhal Jain & Co. CHARTERED ACCOUNTANTS

Independent Auditor's Review Report On consolidated unaudited guarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015

TO THE BOARD OF DIRECTORS OF Parenteral Drugs (India) Limited

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Parenteral Drugs (India) Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended 30th June, 2019 and for the period from 1st April, 2019 to 30th June, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended5. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended and the corresponding period from 1st April, 2019 to 30th June, 2019, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review6.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities: Parenteral Drugs (India) Limited, Parenteral Impex Limited, Parenteral Biotech Limited.

UDIN406604AAAAAF3981

A-18, Indrapurl Colony, Lai Kothi, Tonk Road, Jaipur, 302006 (Raj.) +918233600787, 0141-4010787 Email: - cajainkamal@gmail.com



Singhal Jain & Co.

CHARTERED ACCOUNTANTS

CA KAMAL JAIN FCA, LL.B., M.COM, PGDTL, FAFP

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the Interim financial statements /financial information/ financial results of of two Subsidiaries included in the consolidated unaudited financial results, whose interim financial statements/ financial information/ financial results reflect total revenue of Rs. Nil, total net profit/(loss) after tax of Rs. (-) 0.03 laks and total comprehensive income / loss of Rs. Nil for the guarter ended 30th June 2019 as considered in the consolidated unaudited financial results have not been reviewed by us. These Interim financial statements / financial information/ financial results have not been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

For Singhal Jain & Co. Chartered Accountants Firm Regn No.013995C

Karnal Jain (Partner) M. No.406604

Place: Indore Date: 05.08.2019 UDIN: - 19406604242488 3981

> A-18, Indrapuri Colony, Lal Kothi, Tonk Road, Jaipur, 302006 (Raj.) +91 8233600787, 0141-4010787 Email :- cajainkamal@gmail.com